A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With lntravenous Vedolizumab and Oral Upadacitinib Compared With lntravenous Vedolizumab and Oral Placebo for lnduction Followed by lntravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease